Successful Management of Meningitis and Sepsis Due to Multidrug-Resistant Elizabethkingia meningoseptica in an Infant
Abstract
We report a case of a two-month-old male infant, born prematurely, who initially presented with fever, irritability, and elevated inflammatory markers. He was then diagnosed with Elizabethkingia meningoseptica meningitis and sepsis. Treatment included intravenous levofloxacin, ampicillin, and cefotaxime. Despite the bacterium's multidrug resistance and high reported morbidity and mortality rates, the patient made a full recovery with no complications at discharge or follow-up. This case demonstrates the challenges in treating E. meningoseptica infections and highlights the potential clinical efficacy of antibiotic regimens that may not align with standard susceptibility testing.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.